Company Overview of Precision BioSciences, Inc.
Precision BioSciences, Inc., a biotechnology company, engages in developing and commercializing therapeutics and services based on genomic molecular biology. It offers Biotherapeutics, a directed nuclease editor (DNE) therapeutic targeted to enable the in situ correction of genes responsible for human diseases; Biotools, an engineered DNE meganucleases used to engineer cell lines for disease models or optimize cell lines for the biomanufacturing of protein vaccines and therapeutics; and PlantSciences, a custom DNE meganucleases that enable site-specific engineering of row crops and biofuel feedstock. The company was founded in 2006 and is based in Research Triangle Park, North Carolina.
302 East Pettigrew Street
Dibrell Building Suite A-100
Durham, NC 27701
Founded in 2006
Key Executives for Precision BioSciences, Inc.
Co-Founder, Chief Executive Officer and Director
Chief Operations Officer and Chief Financial Officer
Director of Meganuclease Development
Chairman and Chief Scientific Officer
Compensation as of Fiscal Year 2014.
Precision BioSciences, Inc. Key Developments
Precision BioSciences, Inc. Announces Board Appointments
May 11 15
Precision BioSciences, Inc. announced the closing of a $25.6 million Series A financing led by venBio. Joining in the oversubscribed financing are Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, the Longevity Fund, and two well-known public market investors. Robert Adelman of venBio and Ben Auspitz of Fidelity Biosciences will join Precision's Board alongside Precision's Chief Executive Officer, Matthew Kane and Chief Scientific Officer, Derek Jantz.
Danziger Innovations Ltd. and Precision BioSciences, Inc. Announce Successful Genome Modification Collaboration in Ornamental Plants
Mar 20 14
Danziger Innovations Ltd. and Precision BioSciences, Inc. announced that they have successfully generated site-specific genome modifications in petunia and jasmine tobacco by combining Precision's Directed Nuclease Editor (DNE) gene editing technology with Danziger's MemoGene gene delivery system. This successful research effort was aimed at genetic control of flower color but researchers at Precision and Danziger believe that the approach can be used more broadly to address genome engineering challenges in plants that are recalcitrant to existing transformation methods without requiring the insertion of foreign DNA into the plant genome.
Nova Synthetix and Precision BioSciences, Inc. Announce Collaboration to Develop Non-GM, Ricin-Free Castor with Customizable Oil Content
Mar 12 14
Nova Synthetix and Precision BioSciences, Inc. announced that they have initiated a joint research effort to generate non-GM, ricin-free castor plants using Precision's Directed Nuclease Editor (DNE) technology in combination with Nova Synthetix's proprietary plant transformation system. Scientists at Nova Synthetix and Precision also plan to utilize their joint capabilities to generate improved castor variants capable of producing user defined oil profiles for industrial, biofuel, and feed-directed applications. The companies believe that the successful development of this multi-year research effort will address a significant agricultural need and result in a castor plant that is safer and has far greater market utility.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 30, 2015